News
GLP-1 Access and Insurance News
Latest — updated August 10, 2026
Access-lane changes:
Orforglipron widens the approved oral lane
April's approval of the first oral small-molecule GLP-1 (~12% average loss at top dose, no food/water timing rules) adds a second approved pill and new price pressure below the injectables.
Monitored category — items publish only when newsworthy and sourced.
The access-and-insurance category tracks coverage decisions, manufacturer cash-pay programs, and eligibility changes for approved GLP-1 products. Because approved products are a separate class from compounded ones, this category never ranks them together with compounded programs.
What we watch in this category
- Coverage and formulary changes
- Manufacturer direct-access price changes
- Employer and plan benefit shifts
- Eligibility-criteria updates
Primary sources monitored
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.